Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Podichetty JT, Brinda BJ, Nelson RP, Karr AH, Prasad NK, Quinney S, Foxworthy Scott S, Kiel PJ. Pharmacokinetics of Basiliximab for the Prevention of Graft-versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal-Intensity Cyclophosphamide and Fludarabine. Pharmacotherapy 2019;40:26-32. [PMID: 31742732 DOI: 10.1002/phar.2347] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]

For:	Podichetty JT, Brinda BJ, Nelson RP, Karr AH, Prasad NK, Quinney S, Foxworthy Scott S, Kiel PJ. Pharmacokinetics of Basiliximab for the Prevention of Graft-versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal-Intensity Cyclophosphamide and Fludarabine. Pharmacotherapy 2019;40:26-32. [PMID: 31742732 DOI: 10.1002/phar.2347] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]

Number

Cited by Other Article(s)

Le Tilly O, Gatault P, Baron C, Bejan‐Angoulvant T, Büchler M, Paintaud G, Ternant D. Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target‐mediated drug disposition (TMDD) model. Br J Clin Pharmacol 2022;88:3500-3505. [DOI: 10.1111/bcp.15235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Revised: 01/02/2022] [Accepted: 01/09/2022] [Indexed: 11/29/2022] Open